OBJECTIVE To evaluate the influence of G2677T/A genetic polymorphisms on cyclosporine pharmacokinetics and pharmacodynamics. METHODS Cochrane library，Pubmed， EMBASE， CNKI databases were searched by computer for investigating the influence of G2677T/A genetic polymorphisms on cyclosporine pharmacokinetics and pharmacodynamics. The researches were reported before October 2008. The Meta-analysis was performed by Revman 5.0 software. RESULTS Seven retrospective studies， with 5 literatures in English and 2 literatures in Chinese， included 844 renal transplant recipients. The results of Meta-analysis showed： The GG genotype had lower dose-adjusted c0 levels than any other genotype (P<0.05). Statistical difference was observed between GG genotypes and (TT+TA+AA) genotypes in mean dose-adjusted c2 levels and daily dose (P<0.05)， but it was not observed between GG genotype and (GT+GA) genotype (P>0.05). G2677T/A genetic polymorphisms were not association with the rates of acute rejection (P>0.05). CONCLUSION G2677T/A genetic polymorphisms affect the cyclosporine exposure. No association between G2677T/A genetic polymorphisms and the rates of acute rejection. High-quality and large-scale prospective studies are needed.
TNG Hui-lin;HU Yong-fng;ZHNG Ting.
Influence of MDR1G2677T/A Genetic Polymorphisms on Cyclosporine Pharmacokinetics and Pharmacodynamics： A Systematic Review[J]. Chinese Pharmaceutical Journal, 2010, 45(2): 140-143
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ HALLORAN P F. Immunosuppressive drugs for kidney transplantation ［J］.N Engl J Med， 2004，351(26)：2715-2729. ［2］ HESSELINK D A， SMAK GREGOOR P J， WEIMAR W. The use of cyclosporine in renal transplantation ［J］.Transplant Proc， 2004， 36 (Suppl 2)：99-106. ［3］ KAHAN B D， KEOWN P， LEVY G A， et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice ［J］. Clin Ther， 2002， 24 (3)： 329-350. ［4］ KEOWN P A. New concepts in cyclosporine monitoring ［J］. Curr Opin Nephrol Hypertens， 2002， 11(6)： 619-629. ［5］ HU Y F， ZHOU H H. Contribution of genetic polymorphisms of the CYP3A4， CYP3A5 and MDR1 genes to cyclosporine disposition ［J］. Chin Pharmacol Bull（中国药理学通报），2005，21(3)：257-261. ［6］ HASHIDA T， MAUDA S， UCMOTO S， et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation ［J］.Clin Pharmacol Ther， 2001， 69 (5)：308-316. ［7］ ANGLICHEAU D， THERVET E， ETIENNE I， et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation ［J］. Clin Pharmacol Ther， 2004， 75(5)：422-433. ［8］ HAUFROID V， MOURAD M， VAN KERCKHOVE V， et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients ［J］. Pharmacogenetics， 2004， 14(3)：147-154. ［9］ WANG W， GUAN D L， ZHANG X D， et al. Study of relationship between MDR1 polymorph ism and the application of immunosuppressant ［J］. Chin J Urol(中华泌尿外科杂志)， 2006， 27（Suppl 1）：89-91. ［10］ FREDERICKS S， JORGA A M， MACPHEE I A M， et al. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements［J］. Clin Transplant， 2007， 21(2)：252-257. ［11］ SINGH R， KESARWANI P， SRIVASTAVA A， et al. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India［J］. Arch Med Res， 2008， 39(7)：695-701. ［12］ QIU X Y， JIAO Z， ZHANG M， et al. Association of MDR1， CYP3A4*18B， and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients［J］. Eur J Clin Pharmacol， 2008， 64(11)：1069-1084. ［13］ FANG J， CHEN B， ZHANG W， et al. Relationship between multi-drug resistance gene polymorphism and blood concentration of cyclosporin in renal transplantation patients［J］. Chin J Clin Pharm (中国临床药学杂志)， 2008， 17(5)：265-269. ［14］ HOFFEMYER S， BURK O， VON RICHTER O， et al. Functional polymorphisms of the human multidrug-resistance gene： multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo［J］. Proc Natl Acad Sci， 2000， 97(7)：3473-3478. ［15］ WOODAHL E L， RODNEY J Y H. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function［J］. Curr Drug Metab， 2004，5(1)：11-19. ［16］ XIE H G， WOOD A J， KIM R B， et al. Genetic variability in CYP3A5 and its possible consequences［J］. Pharmacogenomics， 2004， 5(3)：243-272. ［17］ HESSELINK D A， VAN SCHAIK R H， HEIDEN I P， et al. Genetic polymorphisms of the CYP3A4， CYP3A5， and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus［J］. Clin Pharmacol Ther， 2003, 74(3)：245-254. ［18］ KREUTZ R， ZURCHER H， KAIN S， et al. The effect of variable CYP3A5 expression on cyclosporine dosing， blood pressure and long-term graft survival in renal transplant patients［J］. Pharmacogenetics， 2004， 14(10)：665-671. ［19］ ZHAO Y， SONG M， GUAN D， et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus［J］. Transplant Proc， 2005，37(1)：178-181. ［20］ HU Y F， QIU W， LIU Z Q， et al. Effects of genetic polymorphisms of CYP3A4， CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation［J］. Clin Exp Pharmacol Physiol， 2006， 33(11)：1093-1098. ［21］ LOH P T， LOU H X， ZHAO Y， et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in asian renal transplant recipients［J］. Transplant Proc， 2008， 40(5)：1690-1695. ［22］ JIN Z， ZHANG W X， CHEN B， et al. Effect of CYP3A5 and MDR1 gene polymorph ism on concentration /dose ratios of tacrolimus in Chinese liver transplant patients［J］. Chin Pharm J(中国药学杂志)， 2008，43(9)：649-653.
PDF(681 KB)
